Behavioral
The Charlotte Hungerford Hospital
The Charlotte Hungerford Hospital was paid $89.43M by Medicaid between Jan 2018 and Dec 2024, across 481 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoTHE CHARLOTTE HUNGERFORD HOSPITAL
TORRINGTON, CT 06790
TORRINGTON, CT 06790
33aNPI1629075734assigned 07/05/2005
33bProvider typeBehavioral Analyst
28Total paid$89.43M
24GClaims1,925,033
24DCodes billed481
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Behavioral Analyst providers in Connecticut
Rank by total paid#1 of 42
Median peer was paid$264K
This provider vs. median339×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 262,777 | $10.70M | |
| 2019 | 266,688 | $10.72M | |
| 2020 | 240,831 | $9.79M | |
| 2021 | 276,505 | $13.07M | |
| 2022 | 281,268 | $14.46M | |
| 2023 | 310,331 | $15.83M | |
| 2024incomplete | 286,633 | $14.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 43,156 | 37,997 | $18.57M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 66,621 | 60,560 | $12.38M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.0% | 92,126 | 75,451 | $6.23M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.9% | 39,916 | 36,116 | $6.19M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.6% | 55,738 | 15,102 | $3.18M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 22,949 | 19,287 | $3.11M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.1% | 57,168 | 52,806 | $2.75M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.7% | 36,551 | 23,037 | $2.38M |
| S9480 | Intensive outpatient psychiatric services, per diem | 2.5% | 20,664 | 3,475 | $2.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 6,999 | 6,305 | $1.63M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.6% | 9,117 | 8,235 | $1.39M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 10,857 | 9,947 | $1.21M |
469 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 22,517 | $1.11M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.2% | 3,771 | $1.08M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 3,279 | $1.05M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 6,499 | $1.02M |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 31,310 | $939K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,008 | $884K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 4,599 | $781K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 7,672 | $738K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,161 | $698K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 6,188 | $665K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,121 | $652K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,427 | $638K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 9,070 | $616K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,070 | $550K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,481 | $512K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,236 | $510K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,841 | $498K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,165 | $494K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 799 | $473K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,520 | $453K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,980 | $444K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 21,258 | $429K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 4,452 | $372K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,644 | $358K |
| 97035 | <1% | 8,877 | $358K | |
| 97161 | <1% | 5,745 | $348K | |
| H2012 | Behavioral health day treatment, per hour | <1% | 7,343 | $337K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 7,226 | $298K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 491 | $293K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 29,330 | $291K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,920 | $281K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 735 | $263K |
| 76641 | <1% | 2,827 | $259K | |
| 11056 | <1% | 6,403 | $256K | |
| 59025 | Fetal non-stress test | <1% | 1,839 | $251K |
| 64615 | <1% | 2,248 | $250K | |
| 76770 | <1% | 2,878 | $243K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 18,899 | $242K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,603 | $239K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,562 | $239K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 645 | $236K |
| 90837 | Psychotherapy session, about an hour | <1% | 2,630 | $228K |
| 97010 | <1% | 10,225 | $225K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 442 | $212K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 6,140 | $180K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 759 | $169K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,591 | $168K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,954 | $162K |
| 77065 | Tomosynthesis, mammo | <1% | 1,584 | $155K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 5,288 | $155K |
| 76830 | Ultrasound, transvaginal | <1% | 1,516 | $148K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,682 | $146K |
| 97014 | <1% | 3,189 | $142K | |
| 93971 | <1% | 2,098 | $141K | |
| 94010 | <1% | 3,177 | $139K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,616 | $139K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,298 | $132K |
| 11721 | <1% | 17,287 | $129K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,446 | $127K |
| 76536 | <1% | 1,933 | $123K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 8,422 | $122K |
| 97597 | <1% | 2,235 | $120K | |
| 71250 | <1% | 2,174 | $119K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 42,352 | $119K |
| 52000 | <1% | 425 | $117K | |
| 77066 | Tomosynthesis, mammo | <1% | 978 | $111K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,035 | $110K |
| 94060 | <1% | 869 | $109K | |
| 93017 | <1% | 1,644 | $106K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,497 | $106K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,269 | $100K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 968 | $96K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 2,195 | $92K |
| 97162 | <1% | 2,563 | $92K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,430 | $92K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 550 | $89K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 3,158 | $85K |
| 76642 | <1% | 1,091 | $80K | |
| 0002A | <1% | 2,332 | $79K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 2,772 | $77K |
| 0001A | <1% | 2,514 | $77K | |
| 31575 | <1% | 744 | $76K | |
| 99223 | Prolong inpt eval add15 m | <1% | 1,265 | $72K |
| 73630 | <1% | 6,493 | $62K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38,614 | $60K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 220 | $60K |
| 80053 | Comprehensive metabolic panel | <1% | 54,206 | $60K |
| 80061 | Lipid panel | <1% | 6,819 | $56K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,041 | $54K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,212 | $54K |
| 72110 | <1% | 1,031 | $53K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,647 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,010 | $45K |
| 95816 | <1% | 283 | $43K | |
| 70486 | <1% | 734 | $43K | |
| 92557 | <1% | 2,359 | $38K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,142 | $36K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,265 | $33K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 325 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,843 | $31K |
| 72100 | <1% | 1,636 | $31K | |
| 93798 | <1% | 447 | $31K | |
| 73030 | <1% | 2,475 | $30K | |
| 86900 | <1% | 2,938 | $30K | |
| 93975 | <1% | 142 | $30K | |
| 73564 | <1% | 1,402 | $29K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,481 | $29K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 61,454 | $28K |
| 97165 | <1% | 392 | $28K | |
| 76857 | <1% | 296 | $28K | |
| 10060 | <1% | 203 | $28K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,585 | $27K |
| 93976 | <1% | 290 | $26K | |
| 95806 | <1% | 349 | $26K | |
| 73610 | <1% | 2,612 | $26K | |
| 97116 | <1% | 1,616 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 816 | $26K |
| 98968 | <1% | 689 | $25K | |
| 98967 | <1% | 940 | $24K | |
| 72141 | <1% | 103 | $24K | |
| 76801 | <1% | 221 | $24K | |
| 74183 | <1% | 63 | $23K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 98 | $23K |
| 73130 | <1% | 2,198 | $23K | |
| 73502 | <1% | 1,845 | $22K | |
| 74018 | <1% | 1,638 | $22K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,220 | $21K |
| 69210 | <1% | 1,689 | $21K | |
| 93970 | <1% | 155 | $19K | |
| 97166 | <1% | 574 | $19K | |
| 73110 | <1% | 1,483 | $19K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,082 | $18K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,090 | $18K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 254 | $18K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,690 | $17K |
| 70491 | <1% | 103 | $16K | |
| 0004A | <1% | 437 | $16K | |
| 70496 | <1% | 171 | $15K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,894 | $14K |
| 85027 | <1% | 5,890 | $14K | |
| 20553 | <1% | 119 | $14K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 100 | $12K |
| 99221 | <1% | 408 | $12K | |
| 99217 | <1% | 383 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 889 | $11K |
| 84439 | <1% | 2,432 | $11K | |
| G0378 | Hospital observation service, per hour | <1% | 12,443 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,020 | $10K |
| 84403 | <1% | 555 | $9K | |
| 73562 | <1% | 1,252 | $9K | |
| 73140 | <1% | 963 | $9K | |
| 90785 | <1% | 671 | $9K | |
| 82947 | <1% | 4,279 | $9K | |
| 72050 | <1% | 192 | $8K | |
| 31231 | <1% | 135 | $8K | |
| 82607 | <1% | 1,197 | $8K | |
| 95811 | <1% | 12 | $8K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 387 | $8K |
| 78451 | <1% | 16 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 136 | $8K |
| 64493 | <1% | 16 | $7K | |
| 11750 | <1% | 30 | $7K | |
| 86618 | <1% | 1,897 | $7K | |
| 86803 | <1% | 711 | $6K | |
| 0031A | <1% | 247 | $6K | |
| 0064A | <1% | 176 | $6K | |
| 82728 | <1% | 876 | $6K | |
| 99254 | <1% | 69 | $6K | |
| 83655 | <1% | 515 | $5K | |
| 99443 | <1% | 575 | $5K | |
| 84153 | <1% | 537 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 85 | $5K |
| 94375 | <1% | 2,312 | $5K | |
| 10061 | <1% | 13 | $5K | |
| 84402 | <1% | 282 | $5K | |
| 85610 | <1% | 7,563 | $4K | |
| 99245 | <1% | 29 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,102 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,048 | $4K |
| 72040 | <1% | 220 | $4K | |
| 84702 | <1% | 3,880 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 123 | $4K |
| 0003A | <1% | 107 | $4K | |
| 93880 | <1% | 49 | $4K | |
| 82746 | <1% | 619 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,811 | $4K |
| 73560 | <1% | 143 | $4K | |
| 95251 | <1% | 390 | $3K | |
| 84152 | <1% | 384 | $3K | |
| 82627 | <1% | 243 | $3K | |
| 84481 | <1% | 354 | $3K | |
| 20611 | <1% | 16 | $3K | |
| 73080 | <1% | 334 | $3K | |
| 83550 | <1% | 731 | $3K | |
| 86780 | <1% | 300 | $3K | |
| 83540 | <1% | 914 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 89 | $3K |
| 80076 | <1% | 999 | $3K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 2,831 | $3K |
| 82043 | <1% | 1,087 | $3K | |
| 88112 | <1% | 437 | $3K | |
| 0012A | <1% | 112 | $3K | |
| 97032 | <1% | 44 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,527 | $3K |
| 0011A | <1% | 105 | $2K | |
| 92567 | <1% | 4,777 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16,415 | $2K |
| 82570 | <1% | 1,018 | $2K | |
| 87088 | <1% | 2,537 | $2K | |
| 86140 | <1% | 2,302 | $2K | |
| 99220 | <1% | 51 | $2K | |
| 88342 | <1% | 841 | $2K | |
| 87077 | <1% | 4,206 | $2K | |
| 11055 | <1% | 40 | $2K | |
| 71101 | <1% | 434 | $2K | |
| 95819 | <1% | 13 | $2K | |
| 93225 | <1% | 27 | $2K | |
| 87081 | <1% | 2,128 | $2K | |
| 92552 | <1% | 73 | $2K | |
| 94727 | <1% | 913 | $2K | |
| 76870 | <1% | 45 | $2K | |
| 11720 | <1% | 225 | $2K | |
| 86038 | <1% | 260 | $2K | |
| 87186 | <1% | 3,236 | $2K | |
| 97799 | <1% | 897 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 158 | $2K |
| 93270 | <1% | 121 | $2K | |
| 90674 | <1% | 174 | $2K | |
| 85651 | <1% | 1,115 | $2K | |
| 83516 | <1% | 211 | $2K | |
| 93016 | <1% | 209 | $2K | |
| 87340 | <1% | 270 | $2K | |
| 99441 | <1% | 136 | $2K | |
| 90686 | <1% | 202 | $2K | |
| 84270 | <1% | 100 | $1K | |
| 12001 | <1% | 866 | $1K | |
| 97012 | <1% | 21 | $1K | |
| 83690 | <1% | 13,515 | $1K | |
| 0071A | <1% | 35 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 621 | $1K |
| 82550 | <1% | 1,915 | $1K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 456 | $1K |
| 97163 | <1% | 32 | $1K | |
| 83735 | <1% | 13,133 | $1K | |
| 99218 | <1% | 39 | $1K | |
| 86617 | <1% | 262 | $1K | |
| 73523 | <1% | 12 | $1K | |
| 0072A | <1% | 30 | $1K | |
| 73590 | <1% | 201 | $1K | |
| 96367 | <1% | 81 | $1K | |
| C9399 | Unclassified drugs or biologicals | <1% | 14 | $1K |
| 81003 | <1% | 27,383 | $1K | |
| 81001 | <1% | 4,640 | $1K | |
| 81050 | <1% | 750 | $1K | |
| 99253 | <1% | 15 | $1K | |
| 82565 | <1% | 4,681 | $889.38 | |
| 51798 | <1% | 1,254 | $883.30 | |
| 84146 | <1% | 60 | $814.44 | |
| 70498 | <1% | 183 | $807.76 | |
| 29125 | <1% | 211 | $778.67 | |
| 85018 | <1% | 1,550 | $775.63 | |
| 80164 | <1% | 169 | $773.68 | |
| 87070 | <1% | 1,911 | $765.11 | |
| 95886 | <1% | 176 | $746.72 | |
| 82784 | <1% | 135 | $745.92 | |
| 86666 | <1% | 165 | $738.72 | |
| 86850 | <1% | 2,549 | $722.26 | |
| 85730 | <1% | 1,023 | $689.93 | |
| 94729 | <1% | 911 | $658.35 | |
| 99442 | <1% | 143 | $574.40 | |
| 0054A | <1% | 17 | $560.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 209 | $540.05 |
| 85652 | <1% | 1,176 | $520.60 | |
| 83880 | <1% | 3,744 | $504.59 | |
| 82075 | <1% | 84 | $494.93 | |
| 82140 | <1% | 208 | $459.36 | |
| 99252 | <1% | 13 | $449.57 | |
| 82040 | <1% | 191 | $444.26 | |
| 0124A | <1% | 13 | $440.00 | |
| 86705 | <1% | 44 | $438.75 | |
| 86769 | <1% | 14 | $421.30 | |
| 85007 | <1% | 724 | $406.59 | |
| 90839 | <1% | 1,307 | $403.75 | |
| 88108 | <1% | 138 | $399.67 | |
| 82150 | <1% | 274 | $396.16 | |
| 84550 | <1% | 300 | $375.19 | |
| 76376 | <1% | 2,897 | $374.73 | |
| 87427 | <1% | 58 | $366.40 | |
| 87205 | <1% | 1,925 | $359.63 | |
| 87040 | <1% | 7,688 | $352.44 | |
| 87045 | <1% | 74 | $351.78 | |
| 84484 | <1% | 19,117 | $347.95 | |
| 81025 | <1% | 6,178 | $345.57 | |
| 82105 | <1% | 27 | $336.42 | |
| 87400 | <1% | 213 | $333.80 | |
| 87046 | <1% | 61 | $333.74 | |
| 92610 | <1% | 12 | $323.41 | |
| 99201 | <1% | 44 | $313.65 | |
| 93296 | <1% | 38 | $307.69 | |
| 86901 | <1% | 2,942 | $301.11 | |
| 90715 | <1% | 1,959 | $294.84 | |
| 84100 | <1% | 1,180 | $287.63 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,415 | $279.28 |
| T1016 | Case management, each 15 minutes | <1% | 15 | $270.00 |
| 86709 | <1% | 29 | $268.75 | |
| 99406 | <1% | 312 | $258.80 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 52 | $249.76 |
| 74019 | <1% | 27 | $236.92 | |
| 82977 | <1% | 62 | $229.81 | |
| 84703 | <1% | 5,265 | $225.60 | |
| 93793 | <1% | 95 | $223.41 | |
| 84460 | <1% | 150 | $221.87 | |
| 86431 | <1% | 80 | $211.38 | |
| 73090 | <1% | 57 | $206.49 | |
| 84436 | <1% | 65 | $203.36 | |
| 36600 | <1% | 45 | $196.89 | |
| 86696 | <1% | 16 | $184.80 | |
| 12002 | <1% | 144 | $179.59 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,325 | $165.84 |
| 87075 | <1% | 372 | $161.48 | |
| 80178 | <1% | 47 | $151.44 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 242 | $145.38 |
| 87209 | <1% | 16 | $129.25 | |
| 94618 | <1% | 130 | $127.08 | |
| 83605 | <1% | 8,248 | $123.09 | |
| 80051 | <1% | 338 | $121.07 | |
| 83525 | <1% | 16 | $120.01 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,877 | $118.94 |
| 87147 | <1% | 153 | $118.56 | |
| 86695 | <1% | 16 | $113.40 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 27,064 | $106.92 |
| 82247 | <1% | 87 | $106.83 | |
| 97164 | <1% | 12 | $106.68 | |
| 84145 | <1% | 1,221 | $102.59 | |
| 87177 | <1% | 16 | $93.50 | |
| 86706 | <1% | 16 | $82.08 | |
| 82374 | <1% | 3,376 | $81.33 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 690 | $77.34 |
| 85379 | <1% | 3,144 | $75.54 | |
| 87468 | <1% | 243 | $72.18 | |
| 82962 | <1% | 9,879 | $71.65 | |
| 82248 | <1% | 48 | $65.12 | |
| 84132 | <1% | 3,783 | $64.99 | |
| 84520 | <1% | 4,424 | $63.26 | |
| 82803 | <1% | 667 | $53.15 | |
| 87484 | <1% | 243 | $52.86 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,413 | $51.57 |
| 81002 | <1% | 131 | $51.24 | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 38 | $50.78 |
| 86592 | <1% | 15 | $48.84 | |
| 86308 | <1% | 50 | $39.52 | |
| 84295 | <1% | 3,407 | $36.62 | |
| 94760 | <1% | 1,766 | $35.00 | |
| 87510 | <1% | 28 | $33.59 | |
| 87480 | <1% | 29 | $33.57 | |
| 87641 | <1% | 340 | $33.51 | |
| 87660 | <1% | 29 | $33.51 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,833 | $33.12 |
| 88304 | <1% | 635 | $32.99 | |
| 89055 | <1% | 13 | $32.56 | |
| 82553 | <1% | 194 | $30.16 | |
| 87207 | <1% | 694 | $28.38 | |
| 82435 | <1% | 3,375 | $27.23 | |
| 51702 | <1% | 13 | $25.87 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 19 | $25.25 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 47 | $23.10 |
| 94761 | <1% | 1,888 | $18.98 | |
| 96376 | <1% | 5,758 | $18.59 | |
| 87015 | <1% | 317 | $17.81 | |
| 84450 | <1% | 27 | $17.48 | |
| 80179 | <1% | 414 | $16.44 | |
| 85378 | <1% | 330 | $13.62 | |
| 82077 | <1% | 2,053 | $12.36 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 182 | $11.45 |
| 82375 | <1% | 550 | $11.24 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,214 | $9.61 |
| 83050 | <1% | 516 | $6.69 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,472 | $5.22 |
| 83615 | <1% | 32 | $4.98 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,267 | $3.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,007 | $2.87 |
| J3490 | Unclassified drugs | <1% | 174,985 | $2.27 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,918 | $1.80 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 241 | $1.69 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 212 | $1.50 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,453 | $1.22 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,959 | $1.12 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,716 | $1.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,188 | $0.87 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 21 | $0.11 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 748 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 14 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,355 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 52 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 718 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,028 | $0.00 |
| 76942 | 0% | 114 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,323 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 307 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 77 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 432 | $0.00 |
| 93356 | 0% | 223 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 271 | $0.00 |
| 91300 | 0% | 5,105 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 497 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 518 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 73 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 193 | $0.00 |
| 80143 | 0% | 423 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 12 | $0.00 |
| 87469 | 0% | 83 | $0.00 | |
| 12011 | 0% | 41 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 154 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 127 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 73 | $0.00 |
| 99490 | Ccm add 20min | 0% | 90 | $0.00 |
| 91312 | 0% | 13 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 44 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 27 | $0.00 |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | 0% | 12 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 42 | $0.00 |
| 82805 | 0% | 42 | $0.00 | |
| 87420 | 0% | 20 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 32 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 18 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 15 | $0.00 |
| 82010 | 0% | 14 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 5,079 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 407 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 10,655 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 2,630 | $0.00 |
| C1769 | Guide wire | 0% | 488 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 6,044 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 4,292 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 9,552 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 1,436 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,431 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 4,108 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 165 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 133 | $0.00 |
| 88341 | 0% | 88 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 4,640 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 28 | $0.00 |
| 91303 | 0% | 168 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 1,671 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 130 | $0.00 |
| 91306 | 0% | 176 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 92 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 857 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 131 | $0.00 |
| 91305 | 0% | 17 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 347 | $0.00 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 0% | 13 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 87 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 105 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 358 | $0.00 |
| 91307 | 0% | 65 | $0.00 | |
| 91301 | 0% | 255 | $0.00 | |
| 87807 | 0% | 22 | $0.00 | |
| 93280 | 0% | 30 | $0.00 | |
| 92556 | 0% | 70 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 71 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 26 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 13 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 13 | $0.00 |
| 72020 | 0% | 31 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 33 | $0.00 |
| 29130 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHAPP, SUSAN (CFO)